Patents by Inventor Jan Stenvang

Jan Stenvang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination treatment of cancer
    Patent number: 11903927
    Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: February 20, 2024
    Assignee: Scandion Oncology A/S
    Inventors: Nils Aage Brünner, Palle Christophersen, Jan Stenvang, Jens Lichtenberg, Annemette Thougaard
  • COMBINATION TREATMENT OF CANCER
    Publication number: 20210353596
    Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.
    Type: Application
    Filed: July 29, 2021
    Publication date: November 18, 2021
    Inventors: Nils Aage Brünner, Palle Christophersen, Jan Stenvang, Jens Lichtenberg, Annemette Thougaard
  • Combination treatment of cancer
    Patent number: 11103481
    Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: August 31, 2021
    Assignee: Scandion Oncology A/S
    Inventors: Nils Aage Brünner, Palle Christophersen, Jan Stenvang, Jens Lichtenberg, Annemette Thougaard
  • UREA DERIVATIVES FOR USE IN THE TREATMENT OF SUBJECTS WITH ELEVATED EXPRESSION AND/OR ACTIVITY OF SRPK1
    Publication number: 20210251963
    Abstract: The present invention relates to treatment of diseases characterized by elevated expression and/or activity of SRPK1 with specific SRPK1 inhibitors and to methods for identifying subjects who may benefit from such treatment.
    Type: Application
    Filed: September 6, 2019
    Publication date: August 19, 2021
    Applicant: Scandion Oncology A/S
    Inventors: Nils Aage Brünner, Jan Stenvang
  • COMBINATION TREATMENT OF CANCER
    Publication number: 20190269654
    Abstract: The present invention relates to treatment of cancer, in particular to methods of sensitising cancer cells to an anti-cancer therapy by administering an effective amount of a modulator of Volume Regulated Anion Channels, i.e. a VRAC modulator.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 5, 2019
    Inventors: Nils Aage Brünner, Palle Christophersen, Jan Stenvang, Jens Lichtenberg, Annemette Thougaard
  • MODULATION OF MICRORNA-138 FOR THE TREATMENT OF BONE LOSS
    Publication number: 20160355804
    Abstract: There is provided nucleic acids (mir-138Antimirs) for use in treating or preventing bone loss in a patient. Also there is provided a method for reducing the levels of endogenous mir-138 in a cell.
    Type: Application
    Filed: January 7, 2016
    Publication date: December 8, 2016
    Inventors: Moustapha KASSEM, Basem ABDALLAH, Hanna TAIPALEENMAEKI, Sakari KAUPPINEN, Tilde ESKILDSEN, Jan STENVANG
  • MODULATION OF MICRORNA-138 FOR THE TREATMENT OF BONE LOSS
    Publication number: 20140194491
    Abstract: There is provided nucleic acids (mir-138 Antimirs) for use in treating or preventing bone loss in a patient. Also there is provided a method for reducing the levels of endogenous mir-138 in a cell.
    Type: Application
    Filed: June 11, 2012
    Publication date: July 10, 2014
    Applicant: SYDDANSK UNIVERSITET
    Inventors: Moustapha Kassem, Basem Abdallah, Hanna Taipaleenmaeki, Sakari Kauppinen, Tilde Eskildsen, Jan Stenvang
  • Micro-RNA mediated modulation of colony stimulating factors
    Patent number: 8492357
    Abstract: The present invention relates to the modulation of immunoregulatory proteins, including cytokines, such as colony stimulatory factors (CSF) via the use of microRNA-155 modulators.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: July 23, 2013
    Assignee: Santaris Pharma A/S
    Inventors: Jesper Worm, Jan Stenvang, Susanna Obad, Sakari Kauppinen
  • Micro-RNA Mediated Modulation of Colony Stimulating Factors
    Publication number: 20120115924
    Abstract: The present invention relates to the modulation of immunoregulatory proteins, including cytokines, such as colony stimulatory factors (CSF) via the use of microRNA-155 modulators.
    Type: Application
    Filed: July 24, 2009
    Publication date: May 10, 2012
    Applicant: Santaris Pharma A/S
    Inventors: Jesper Worm, Jan Stenvang, Susanna Obad, Sakari Kauppinen